In vitro evaluation of ganaplacide/lumefantrine combination against Plasmodium falciparum in a context of artemisinin resistance.

ABSTRACT:

Background

Ganaplacide, also known as KAF156, is among the new antimalarial drug candidates that have successfully reached Phase III clinical trials, and is proposed in combination with lumefantrine. This combination could replace the current front-line artemisinin-based combination therapies (ACTs) in case of Plasmodium falciparum resistance to both artemisinins and partner drugs. Indeed, the African continent, where the malaria burden is the highest, is currently experiencing worrying multiple emergences and spread of artemisinin resistance, which urges for the exploration of the antiparasitic properties of KAF156 in this context.

Objectives and methods

The objectives of this work were firstly to evaluate the risk of cross-resistance between artemisinins and KAF156 alone,

SUBMITTER: Manaranche J 

PROVIDER: S-EPMC11531816 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature